LeadZ Therapeutics

LeadZ Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of next-generation biotherapeutics, with a primary emphasis on oncology. The company specializes in antibody-drug conjugates (ADCs) and monoclonal antibodies designed to target specific tumor antigens with high precision. Its lead program, LZ001, is a Claudin 18.2-targeted ADC currently in clinical development for the treatment of advanced solid tumors, including gastric and pancreatic cancers. LeadZ Therapeutics leverages its proprietary research and development platform to create highly potent and selective therapies aimed at addressing unmet medical needs in the global cancer market. The company is led by a team of industry veterans with significant experience in protein engineering and oncology drug development.